Received 6/15/97 Accepted 6/28/97

1. Kerr, J. F., Wyllie, A. H., and Currie, A. R.: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239-257 (1972)

2. Ellis, H. M. and Horvitz, H. R.: Genetic control of programmed cell death in the nematode C. elegans. Cell 44, 817-829 (1986)

3. Hedgecock, E., Sulston, J. E., and Thomson, N.: Mutations affecting programmed cell deaths in the nematode Caenorhabditis elegans. Science 220, 1277-1280 (1983)

4. Hengartner, M. O., Ellis, R. E., and Horvitz, H. R.: Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356, 494-499 (1992)

5. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., and Yuan, J.: Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75, 653-60 (1993)

6. Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R.: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1beta-converting enzyme. Cell 75, 641-652 (1993)

7. Chinnaiyan, A. M. and Dixit, V. M.: The cell-death machine. Curr Biol 6, 555-562 (1996)

8. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J.: Human ICE/CED-3 protease nomenclature. Cell 87, 171 (1996)

9. Kuida, K., Zheng, T. S., Na, S., Kuan, C.-Y., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R. A.: Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384, 368-372 (1996)

10. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S.-S., and Flavell, R. A.: Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000-2003 (1995)

11. Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., Towne, E., Tracey, D., Wardwell, S., Wei, F-Y., Wong, W., Kamen, R. and Seshadri, T.: Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401-411 (1995)

12. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G.: Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res 53, 3976-3985 (1993)

13. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C.: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371, 346-347 (1994)

14. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M.: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801-9 (1995)

15. Earnshaw, W. C.: Apoptosis: lessons from in vitro systems. TiCB 5, 217-219 (1995)

16. Wang, Z.-Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., Schweiger, M., and Wagner, E. F.: Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9, 509-520 (1995)

17. Rao, L., Perez, D., and White, E.: Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135, 1441-1455 (1996)

18. Takahashi, A., Alnemri, E. S., Lazebnik, Y. A., Fernandes-Alnemri, T., Litwack, G., Moir, R. D., Goldman, R. D., Poirier, G. G., Kaufmann, S. H., and Earnshaw, W. C.: Cleavage of lamin A by Mch2alpha but not CPP32: Multiple interleukin 1betaconverting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 93, 8395-8400 (1996)

19. Neamati, A., Fernandez, A., Wright, S., Kiefer, J., and McConkey, D. J.: Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol 154, 1693-1700 (1994)

20. Casciola-Rosen, L. A., Miller, D. K., Anhalt, G. J., and Rosen, A.: Specific cleavage of the 70-kDa protein component of small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem 269, 30757-30760 (1994)

21. Tewari, M., Beidler, D. R., and Dixit, V. M.: CrmA-inhibitable cleavage of the 70 kDa protein component of the U1 small nuclear ribonucleoprotein during Fas-and tumor necrosis factor-induced apoptosis. J Biol Chem 270, 18738-18741 (1995)

22. Song, Q., Less-Miller, S. P., Kumar, S., Zhang, N., Chan, D. W., Smith, G. C. M., Jackson, S. P., Alnemri, E. S., Litwach, G., Khanna, K. K., and Lavin, M. F.: DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J 15, 3238-3246 (1996)

23. Brancholini, C., Benedetti, M., and Schneider, C.: Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases. EMBO J 14, 5179-5190 (1995)

24. Na, S., Chuang, R. H., Tiru, T. G., Hanke, J. H., Bokoch, G. M., and Danley, D. E.: D4-GDI, a substrate for CPP32, is proteolyzed during Fas-induced apoptosis. J Biol Chem 271, 11209-11213 (1996)

25. Emoto, Y., Manome, Y., Meinhardt, G., Kisaki, H., Kharbanda, S., Robertson, M., Ghayur, T., Wong, W. W., Kamen, R., Weichselbaum, R., and Kufe, D.: Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14, 6148-6156 (1995)

26. Wang, X., Zelenski, N. G., Yang, J., Sakai, J., Brown, M. S., and Goldstein, J. L.: Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15, 1012-1020 (1996)

27. Goldberg, Y. P., Nicholson, D. W., Rasper, D. M., Kalchman, M. A., Koide, H. B., Graham, R. K., Bromm, M., Kazemi-Esfajani, P., Thornberry, N. A., Vaillancourt, J. P., and Hayden, M. R.: Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics 13, 442-449 (1996)

28. Rudel, T. and Bokoch, G. M.: Membrane and morphological es in apoptotic cells regulated by caspase-mediated activation of PAK2. Science 276, 1571-1574 (1997)

29. An, B. and Dou, Q. P.: Cleavage of the retinoblastoma protein during apoptosis: An interleukin 1beta- converting enzyme-like protease as candidate. Cancer Res 56, 438-442 (1996)

30. Jänicke, R. U., Walker, P. A., Lin, S. Y., and Porter, G.: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15, 6969-6978 (1996)

31. Lazebnik, Y. A., Cole, S., Cooke, C. A., Nelson, W. G., and Earnshaw, W. C.: Nuclear events of apoptosis in vitro in cell-free mitotic extracts: A model system for analysis of the active phase of apoptosis. J Cell Biol 123, 7-22 (1993)

32. Liu, X. S., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. D.: Induction of apoptotic program in cell-free extracts - requirement for dATP and cytochrome c. Cell 86, 147-157 (1996)

33. Newmeyer, D. D., Farschon, D. M., and Reed, J. C.: Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell 79, 353-64 (1994)

34. Evans, E. K., Lu, W., Strum, S. L., Mayer, B. J., and Kornbluth, S.: Crk is required for apoptosis in xenopus egg extracts. EMBO J 16, 230-241 (1997)

35. Enari, M., Hase, A., and Nagata, S.: Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J 14, 5201-5208 (1995)

36. Martin, S. J., Newmeyer, D. D., Mathias, S., Farschon, D. M., Wang, H. G., Reed, J. C., Kolesnick, R. N., and Green, D. R.: Cell-free reconstitution of fas-, uv radiation- and ceramide-induced apoptosis. EMBO J 14, 5191-5200 (1995)

37. Fearnhead, H. O., McCurrach, M. E., O'Neill, J., Zhang, K., Lowe, S. W., and Lazebik, Y.A.: Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev 11, 1266-1276 (1997)

38. Liu, X., Zou, H., Slaughter, C., and Wang, X.: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89, 175-184 (1997)

39. Hengartner, M. O. and Horvitz, H. R.: C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76, 665-676 (1994)

40. Vaux, D. L., Cory, S., and Adams, J. M.: Bcl-2 gene promotes a haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440-442 (1988)

41. Veis, D. J., Sorenson, C. M., Shutter, J. R., and Korsmeyer, S. J.: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229-40 (1993)

42. Nakayama, K., Nakayama, K., Negishi, I., Kuida, K., Sawa, H., and Loh, D. Y.: Targeted disruption of Bcl-2 alpha beta in mice-occurence of grey hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 91, 3700-3704 (1994)

43. Kamada, S. A. A., Shinto, Y., Tsujimura, T., Takahashi, T., Noda, T., Kitamura, Y., Kondoh, H., and Tsujimoto, Y.: Bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in the thymus and spleen, polysystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 55, 354-359 (1995)

44. Oltvai, Z. N. and Korsmeyer, S. J.: Checkpoints of dueling dimers foil death wishes. Cell 79, 189-192 (1994)

45. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J.: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-19 (1993)

46. Boise, L. H., Gonzalez, G. M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B.: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608 (1993)

47. Yang, E., Zha, J., Jockel, J., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J.: Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 80, 285-291 (1995)

48. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A., and Reed, J. C.: Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80, 279-284 (1995)

49. Chittenden, T., Harrington, E. A., O'Connor, R., Flemington, C., Lutz, R. J., Evan, G. I., and Guild, B. C.: Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374, 733-736 (1995)

50. Farrow, S. N., White, J. H. M., Martinou, I., and Brown, R.: Cloning of a bcl-2 homologue by ionteraction with adenovirus E1B 19K. Nature 374, 731-733 (1995)

51. Kiefer, M. C., Brauer, M. J., Powers, V. C., Wu, J. J., Umansky, S. R., Tomei, L. D., and Barr, P. J.: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374, 736-739 (1995)

52. Boyd, J. M., Gallo, G. J., Elangovan, B., Houghton, A. B., Malstrom, S., Avery, B. J., Ebb, R. G., Subramanian, T., Chittenden, T., Lutz, R. J., and Chinnadurai, G.: Bik1, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11, 1921-1927 (1995)

53. Inohara, N., Ding, L., Chen, S., and Nunez, G.: Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-xL. EMBO J 16, 1686-1694 (1997)

54. Yin, X. M., Oltval, Z. N., and Korsmeyer, S. J.: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369, 321-323 (1994)

55. Cheng, E. H.-Y., Levine, B., Boise, L. H., Thompson, C. B., and Hardwick, J. M.: Bax-independent inhibition of apoptosis by bcl-x(l). Nature 379, 554-556 (1996)

56. Knudson, C. M., Tung, K. S., Tourtellotte, W. G., Brown, G. A., and Korsmeyer, S. J.: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270, 96-99 (1995)

57. Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D., , B. S., Thompson, C. B., Wong, S.-L., Ng, S.-C., and Fesik, S. W.: X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335-341 (1996)

58. Chittenden, T., Flemington, C., Houghton, A. B., Ebb, R. G., Gallo, G. J., Elangovan, B., Chinnadurai, G., and Lutz, R. J.: A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein biding functions. EMBO J 14, 5589-5596 (1995)

59. Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., , B. S., Minn, A. J., Thompson, C. B., and Fesik, S. W.: Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983-986 (1997)

60. Parker, M. W. and Pattus, F.: Rendering a membrane protein soluble in water: a common packing motif in bacterial protein toxins. TiBS 18, 391-395 (1993)

61. London, E.: Diphteria toxin: membrane interaction and membrane translocation. Biochim Biophys Acta 1113, 25-51 (1992)

62. Minn, A. J., Velez, P., Schendel, S. L., Liang, H., Muchmore, S. W., Fesik, S. W., Fill, M., and Thompson, C. B.: Bcl-xL forms an ion channel in synthetic lipid membranes. Nature 385, 353-357 (1997)

63. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J.: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75, 241-251 (1993)

64. Kane, D. J., Sarafin, T. A., Auton, S., Hahn, H., Gralla, F. B., Valentine, J. C., Ord, T., and Bredesen, D. E.: Bcl-2 inhibition of neural cell death: decreased generation of reacive oxygen species. Science 262, 1274-1276 (1993)

65. Shimizu, S., Eguchi, Y., Kosaka, H., Kamiike, W., Matsuda, H., and Tsujimoto, Y.: Prevention of hypoxia-induced cel death by Bcl-2 and Bcl-xL. Nature 374, 811-813 (1995)

66. Jacobson, M. D. and Raff, M. C.: Programmed cell death and Bcl-2 protection in very low oxygen. Nature 374, 814-816 (1995)

67. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W., and Reed, J. C.: Investigations of the subcellular distribution of the BCL-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum and other mitochondrial membranes. Cancer Res 53, 4701-4714 (1993)

68. Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H., and Cory, S.: Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14, 6136-6147 (1995)

69. Gajewski, T. F. and Thompson, C. B.: Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 87, 589-592 (1996)

70. May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., and Davidson, N. E.: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 in association with suppression of apoptosis. J Biol Chem 269, 26865-26870 (1994)

71. Haldar, S., Jena, N., and Croce, C. M.: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA92, 4507-4511 (1995)

72. Wang, H.-G., Rapp, U. R., and Reed, J. C.: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87, 629-638 (1996)

73. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J.: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87, 619-628 (1996)

74. Chinnaiyan, A. M., O'Rourke, K., Lane, B. R., and Dixit, V. M.: Interaction of CED-4 with CED-3 and CED-9: A molecular framework for cell death. Science 275, 1122-1126 (1997)

75. Wu, D., Wallen, H. D., and Nunez, G.: Interaction and regulation of subcellular localization of CED-4 and CED-9. Science 275, 1126-1129 (1997)

76. Spector, M. S., Desnoyers, S., Hoeppner, D. J., and Hengartner, M. O.: Interaction between the C. elegans cell-death regulators CED-9 and CED-4. Nature 385, 653-656 (1997)

77. Shaham, S. and Horvitz, H. R.: An alternatively spliced c-elegans CED-4 RNA encodes a novel cell death inhibitor. Cell 86, 201-208 (1996)

78. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T.-I., Jones, D. P., and Wang, X.: Prevention of Apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275, 1129-1132 (1997)

79. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D.: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136 (1997)

80. Susin, S. A., Zamzami, N., Castedo, M., Hirsch, T., Marchetti, P., Macho, A., Daugas, E., Geuskens, M., and Kroemer, G.: Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 184, 1331-1341 (1996)

81. Nagata, S. and Suda, T.: Fas and Fas ligand: lpr and gld mutations. Immun Today 16, 39 (1995)

82. Nagata, S.: Apoptosis by death factor. Cell 88, 355-365 (1997)

83. Rozzo, S. J., Eisenberg, R. A., Cohen, P. L., and B.L., K.: Development of the T cell receptor repertoir in lpr mice. Semin Immunol 6, 19-26 (1994)

84. Fisher, G. H., Rosenberg, F. J., Straus, S. E., Dale, J. K., Middleton, L. A., Lin, A. Y., Strober, W., Lenardo, M. J., and Puck, J. M.: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946 (1995)

85. Rieux, L. F., Le, D. F., Hivroz, C., Roberts, I. A., Debatin, K. M., Fischer, A., and de Villartay, J.P.: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349 (1995)

86. Benoist, C. and Mathis, D.: Cell death mediators in autoimmune diabetes-no shortage of suspects. Cell 89, 1-3 (1997)

87. Chernovsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A., and Matis, L. A.: The role of Fas in autoimmune diabetes. Cell 89, 17-24 (1997)

88. Brunner, T., Mogil, R., LaFace, D., Yoo, N., Mahboubi, A., Echeverri, F., Martin, S., Force, W., Lynch, D., Ware, C., and Green, D.: Cell-autonomous Fas (CD95)/Fas-ligand interactions mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444 (1995)

89. Dhein, J., Walczak, H., Bäumler, C., Debatin, K., and Krammer, P.: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441 (1995)

90. Ju, S., Panka, D., Cui, H., Ettinger, R., El-Khatib, M., Sherr, D., and Stanger, B.: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448 (1995)

91. Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, A., Seto, Y., and Nagata, S.: The polypeptide encoded by the cDNA for the human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991)

92. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B. C., Ponsting, H., and Krammer, P.H.: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: sequence identity with the Fas antigen. J Biol Chem 267, 10709-10715 (1992)

93. Itoh, N. and Nagata, S.: A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 268, 10932-10937 (1993)

94. Tartaglia, L. A., Ayres, T. M., Wong, G. H. W., and Goeddel, D. V.: A novel domain within the 55kd TNF receptor signals cell death. Cell 74, 845-853 (1993)

95. Boldin, M., Varfolomeev, E., Pancer, Z., Mett, I., Camonis, J., and Wallach, D.: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 270, 7795-7798 (1995)

96. Chinnaiyan, A., O'Rourke, K., Tewari, M., and Dixit, V.: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505-512 (1995)

97. Hsu, H., Xiong, J., and Goeddel, D. V.: The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81, 495-504 (1995)

98. Stanger, B. Z., Leder, P., Lee, T. H., Kim, E., and Seed, B.: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81, 513-523 (1995)

99. Hsu, H. L., Shu, H. B., Pan, M. G., and Goeddel, D. V.: TRADD-TRAF2 and tradd-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299-308 (1996)

100. Huang, B., Eberstadt, M., Olejniczak, E. T., Meadows, R. P., and Fesik, S. W.: NMR structure and mutagenesis of the Fas (Apo-1/CD95) death domain. Nature 384, 638-641 (1996)

101. Feinstein, E. and Kimchi, A.: The death domain: a module shared by proteins with diverse cellular functions. TiBS 20, 342-344 (1995)

102. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D.: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1- and TNF receptor-induced cell death. Cell 85, 803-815 (1996)

103. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., Orourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M.: Flice, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 85, 817-827 (1996)

104. Chinnaiyan, A. M., O'Rourke, K., Yu, G.-L., Lyons, R. H., Garg, M., Duan, D. R., Zing, L., Gentz, R., Ni, J., and Dixit, V. M.: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990-992 (1996)

105. Kitson, J., Raven, T., Jaing, Y.-P., Goeddel, D. V., Giles, K. M., Pun, K.-T., Grinham, C. J., Brown, R., and Farrow, S. N.: A death-domain-containing receptor that mediates apoptosis. Nature 384, 372-375 (1996)

106. Marsters, S. A., Sheridan, J.P., Donahue, C.J., Pitti, R.M., Gray, C.L., Goddard, A.D., Bauer, K.D., and Ashkenazi, A.: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappaB. Curr Biol 6, 1669-1676 (1996)

107. Thome, M., Schneider, P., Hofmann, K., Fickenscher, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J. L., Schroter, M., Scaffidi, C., Krammer, P. H., Peter, M. E., and Tschopp, J.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517-521 (1997)

108. Wiley, S. R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., Sutherland, G.R., Smith, T.D., Rauch, C., and Smith, C.A.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995)

109. Bodmer, J.-L., Burns, K., Schneider, P., Hofmann, K., Steiner, V., Thome, M., Bornand, T., Hahne, M., Schroter, M., Becker, K., Wilson, A., French, L.E., Browning, J.L., MacDonald, H.R. and Tschopp J.: TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 6, 79-88 (1997)

110. Rothe, M., Sarma, V., Dixit, V. M., and Goeddel, D. V.: TRAF2-mediated activation of NK-kappa B by TNF receptor 2 and CD40. Science 269, 1424-1427 (1995)

111. Duan, H. and Dixit, V. M.: RAIDD is a new 'death' adaptor molecule. Nature 385, 86-89 (1997)

112. Beg, A. A. and Baltimore, D.: An essential role for NF-kappaB in preventing TNF-alpha induced cell death. Science 274, 782-784 (1996)

113. Liu, Z.-G., Hsu, H., Goeddel, D. V., and Karin, M.: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87, 565-576 (1996)

114. Wang, C. Y., Mayo, M. W., and Baldwin, A. S.: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274, 724 (1996)

115. Santana, P., Pena, L. A., Haimovitzfriedman, A., Martin, S., Green, D., Mcloughlin, M., Cordoncardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R.: Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86, 189-199 (1996)

116. Bose, R., Verheij, M., Haimovitz, F. A., Scotto, K., Fuks, Z., and Kolesnick, R.: Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82, 405-414 (1995)

117. Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., Vermeersch, S., Rousse, A., and Laurent, G.: Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 15, 2417-2424 (1996)

118. Tepper, C. G., Jayadev, S., Liu, B., Bielawska, A., Wolff, R., Yonehara, S., Hannun, Y. A., and Seldin, M. F.: Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. Proc Natl Acad Sci USA 92, 8443-8447 (1995)

119. Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun, Y. A.: Programmed cell death induced by ceramide. Science 259, 1769-1771 (1993)

120. Pronk, G. J., Ramer, K., Amiri, P., and Williams, L. T.: Requirement of an ice-like protease for induction of apoptosis and ceramide generation by REAPER. Science 271, 808-810 (1996)

121. Juo, P., Kuo, C. J., Reynolds, S. E., Konz, R. F., Raingeaud, J., Davis, R. J., Biemann, H. P., and Blenis, J.: Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 17, 24-35 (1997)

122. Martin, S. J. and Green, D. R.: Protease activation during apoptosis: death by a thousand cuts? Cell 82, 349-52 (1995)

123. Enari, M., Talanian, R. V., Wong, W. W., and Nagata, S.: Sequential activation of ice-like and CPP32-like proteases during fas-mediated apoptosis. Nature 380, 723-726 (1996).

124. Itoh, N., Tsujimoto, Y., and Nagata, S.: Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol 151, 621-627 (1993)

125. Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., and Thompson, C. B.: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 3, 87-98 (1995)

126. Rodriguez, I., Matsuura, K., Khatib, K., Reed, J. C., Nagata, S., and Vassalli, P.: A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 183, 1031-1036 (1996)

127. Krippner, A., Matsuno-Yagi, A., Gottlieb, R., and Babior, B.: Loss of function of cytochrome c in Jurkat cells undergoing Fas-mediated apoptosis. J Biol Chem 271, 21629-21636 (1996)

128. Oppenheim, R. W.: Neurotrophic survival molecules for motorneuons: An embarrassment of riches. Neuron 17, 195-197 (1996)

129. Yao, R. and Cooper, G. M.: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 267, 2003-2006 (1995)

130. Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kaslaukas, A., Morrison, P. K., Kaplan, D. R., and Tsichlis, P. N.: The protein kinase encoded by the Akt proto-Oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736 (1995)

131. Yao, R. and Cooper, G. M.: Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70(S6K) activity. Oncogene 13, 343-351 (1996)

132. Dudek, H., Datta, S. R., Frank, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E.: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661-664 (1997)

133. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C.: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119-128 (1992)

134. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N.: The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11, 701-713 (1997)

135. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., Downward, J., and Evan, G. I.: Suppression of c-Myc-induced apoptosis by Ras signaling through PI(3)K and PKB. Nature 385, 544-548 (1997)

136. Franke, T. F., Kaplan, D. R., and Cantley, L. C.: P13K: Downstream AKTion blocks apoptosis. Cell 88, 435-437 (1997)

137. Alessi, D. r., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., and Cohen, P.: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B. Curr Biol 7, 261-269 (1997)

138. Kwaja, A., Rodriguez-Viciana, P., Wennström, S., Warne, P. H., and Downward, J.: Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16, 2783-2793 (1997)

139. Marcu, K. B., Bossone, S. A., and Patel, A. J.: myc function and regulation. Annu Rev Biochem 61, 809-860 (1992)

140. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L.: Constitutive c-myc expression in an IL-3-dependent myeloid cell line sppresses cell cycle arrest and accelerates apoptosis. Oncogene 6, 1915-1922 (1991)

141. Shi, Y., Glynn, J. M., Guilbert, L. J., Cotter, T. G., Bissonnette, R. P., and Green, D. R.: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257, 212-214 (1992)

142. Reed, J. C., Cuddy, M., Haldar, S., Croce, C., and Nowell, P.: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: Synergy with Myc and inhibition by BCL2 antisense. Proc Natl Acad Sci USA 87, 3660-3664 (1990)

143. Strasser, A., Harris, A. W., Bath, M. L., and Cory, S.: Novel primitive lymphoid tumors induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333 (1990)

144. McDonnell, T. J. and Korsmeyer, S. J.: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349, 254-256 (1991)

145. Canman, C. E. and Kastan, M. B.: Induction of apoptosis by tumor suppressor genes and oncogenes. Sem Cancer Biol 6, 17-25 (1995)

146. Shen, Y. and Shenk, T. E.: Viruses and apoptosis. Curr Opin Genetics Dev 5, 105-111 (1995)

147. Hunter, T.: Oncoprotein Networks. Cell 88, 333-346 (1997)

148. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M.: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991)

149. Levy, N., Yonish-Rouach, E., Oren, M., and Kimchi, A.: Complementation by wild-type p53 of interleukin-6 effects on M1 cells-induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 13, 7942-7952 (1993)

150. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E.: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993)

151. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993)

152. Lotem, J. and Sachs, L.: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82, 1092-1096 (1993)

153. Lee, J. M. and Bernstein, A.: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90, 5742-5746 (1993)

154. Wagner, A. J., Kokontis, J. M., and Hay, N.: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 8, 2817-2830 (1994)

155. Hermeking, H. and Eick, D.: Mediation of c-Myc-induced apoptosis by p53. Science 265, 2091-2093 (1994)

156. Canman, C. E., Gilmer, T. M., Coutts, S. B., and Kastan, M. B.: Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9, 600-611 (1995)

157. Symonds, H., Krall, L., Remington, L., Saenz, R. M., Lowe, S., Jacks, T., and Van Dyke, T.: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994)

158. Donehower, L. A., Godley, L. A., Aldaz, M., Pyle, R., Shi, Y.-P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E.: Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9, 882-895 (1995)

159. White, E., Cipriani, R., Sabbatini, P., and Denton, A.: Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 65, 2968-2978 (1991)

160. Lowe, S. W. and Ruley, H. E.: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 7, 535-545 (1993)

161. Rao, L., Debbas, P., Sabbatini, P., Hockenberry, D., Korsmeyer, S., and White, E.: The adenovirus E1A proteins induces apoptosis which is inhibited by the E1B 19K and Bcl-2 proteins. Proc Natl Acad Sci USA 89, 7742-7746 (1992)

162. Debbas, M. and White, E.: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7, 546-554 (1993)

163. zur Hausen, H.: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184, 9-13 (1991)

164. Dyson, N., Howley, P. M., Munger, K., and Harlow, E.: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937 (1989)

165. Whyte, P., Buchkovich, K. J., Horowitz, J. M., Friend, S. H., Raybuck, M., Weinberg, R. A., and Harlow, E.: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334, 124-129 (1988)

166. White, A. E., Livanos, E. M., and Tlsty, T. D.: Differential disruption of genomic integrity and cell cycle regulation of normal fibroblasts by the HPV oncoproteins. Genes Dev 8, 666-677 (1994)

167. Field, S. J., Tsai, F. Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Livingston, D. M., Orkin, S. H., and Greenberg, M. E.: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 85, 549-561 (1996)

168. Yamasaki, L., Jacks, T., BronsonR., Goillot, E., Harlow, E., and Dyson, N. J.: Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85, 537-548 (1996)

169. Weinberg, R. A.: The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995)

170. Wu, X. and Levine, A. J.: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91, 3602-3606 (1994)

171. Shan, B. and Lee, W.-H.: Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 14, 8166-8173 (1994)

172. Kranenburg, O., Vandereb, A., and Zantema, A.: Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 15, 46-54 (1996)

173. Qin, X. Q., Livingston, D. M., Kaelin, W. J., and Adams, P. D.: Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91, 10918-22 (1994)

174. Haas-Kogan, D., Kogan, S. C., Levi, D., Dazin, P., T'Ang, A., Fung, Y. K., and Israel, M. A.: Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 14, 461-472 (1995)

175. Fisher, D. E.: Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542 (1994)

176. Hoang, A. T., Cohen, K. J., Barrett, J. F., Bergstrom, D. A., and Dang, C. V.: Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci USA 91, 6875-6879 (1994)

177. Meikrantz, W., Gisselbrecht, S., Tam, S. W., and Schlegel, R.: Activation of cyclin A-dependent protein kinase during apoptosis. Proc Natl Acad Sci USA 91, 3754-3758 (1994)

178. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., and Greenberg, A. H.: Premature p34cdc2 activation required for apoptosis. Science 263, 1143-1145 (1994)

179. Wang, J. and Walsh, K.: Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 273, 359-361 (1996)

180. Meikrantz, W. and Schlegel, R.: Suppression of apoptosis by dominant negative mutants of cyclin-dependent protein kinases. J Biol Chem 271, 10205-10209 (1996)

181. Bello-Fernandez, C., Packham, G., and Cleveland, J.: The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 90, 7804-7808 (1993)

182. Galaktionov, K., Chen, X. C., and Beach, D.: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382, 511-517 (1996)

183. Rudolph, B., Saffrich, R., Zwicker, J., Henglein, B., Muller, R., Ansorge, W., and Eilers, M.: Activation of cyclin-dependent kinases by myc mediates induction of cyclin a, but not apoptosis. EMBO J 15, 3065-3076 (1996)

184. Packham, G., Porter, C. W., and Cleveland, J. L.: C-myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 13, 461-469 (1996)

185. Evan, G. I., Brown, L., Whyte, M., and Harrington, E.: Apoptosis and the cell cycle. Curr Opin Cell Biol 7, 825-834 (1995)

186. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I.: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13, 3286-3295 (1994)

187. Levine, A. J.: p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997)

188. Smith, M. L., Chen, I.-T., Zhan, Q., Bae, I., Chen, C.-Y., Gilmer, T. M., Kastan, M. B., O'Connor, P. M., and Fornace, A. J.: Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1379 (1994)

189. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B.: WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993)

190. Barak, Y., Juven, T., Haffner, R., and Oren, M.: Mdm2 expression is induced by wild-type p53 activity. EMBO J 12, 461-468 (1993)

191. Wu, X., Bayle, H., Olson, D., and Levine, A. J.: The p53-mdm2 antoregulatory feedback loop. Genes Dev 7, 1126-1132 (1993)

192. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P.: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995)

193. Miyashita, T. and Reed, J. C.: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299 (1995)

194. Caelles, C., Helmberg, A., and Karin, M.: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220-223 (1994)

195. Sabbatini, P., Lin, J., Levine, A. J., and White, E.: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 9, 2184-2192 (1995)

196. Haupt, Y., Rowan, S., Shaulian, E., Vousden, K. H., and Oren, M.: Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9, 2170-2183 (1995)

197. Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G. W., Elmore, L., Yeh, H., Hoeijmakers, J., and Harris, C. C.: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10, 1219-1232 (1996)

198. Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., and Vousden, K. H.: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15, 827-838 (1996)

199. Maheswaran, S., Engelbert, C., Bennett, P., Heinrich, G., and Haber, D. A.: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9, 2143-2156 (1995)

200. Lin, C. Q. and Bissell, M. J.: Multi-faceted regulation of cell differentiation by extracellular matrix. FASEB J 7, 737-744 (1993)

201. Gumbiner, B. M.: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 84, 345-357 (1996)

202. Ruoslahti, E. and Reed, J. C.: Anchorage dependence, integrins, and apoptosis.Cell 77, 477-478 (1994)

203. Hynes, R. O.: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25 (1992)

204. Schwartz, M. A.: Signaling by integrins: implications for tumorigenesis. Cancer Res 53, 1503-1506 (1993)

205. Plantefaber, L. C. and Hynes, R. O.: es in integrin receptors on oncogenically transformed cells. Cell 56, 281-290 (1989)

206. Ben-Ze'ev, A., Farmer, S. R., and Penman, S.: Protein synthesis requires cell-surface contact while nuclear events respond to cell shape in anchorage-dependent fibroblasts. Cell 21, 365-372 (1980)

207. Campisi, J. and Medrano, E. E.: Cell cycle perturbations in normal and transformed fibroblasts. J Cell Physiol 114, 53-60 (1983)

208. Assoian, R. K.: Anchorage-dependent cell cycle progression. J Cell Biol 136, 1-4 (1997)

209. Frisch, S. M. and Francis, H.: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124, 619-626 (1994)

210. Meredith, J. E., Fazeli, B., and Schwartz, M. A.: The extracellular matrix as a cell survival factor. Mol Biol Cell 4, 953-961 (1993)

211. Re, F., Zanetti, A., Sironi, M., Polentarutti, N., Lanfrancone, L., Dejana, E., and Colotta, F.: Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 127, 537-546 (1994)

212. Boudreau, N., Sympson, C. J., Werb, Z., and Bissell, M. J.: Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267, 891-893 (1995)

213. Alexander, C. M., Howard, E. W., Bissell, M. J., and Werb, Z.: Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol 135, 1669-1677 (1996)

214. Patterton, D., Hayes, W. P., and Shi, Y.-B.: Transcriptional activation of the metalloproteinase gene stromelysin-3 coincides with thyroid hormone-induced cell death during frog metamorphosis. Dev Biol 167, 252-262 (1995)

215. Coucouvanis, E. and Martin, G. R.: Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Cell 83, 279-287 (1995)

216. Montgomery, A. M. P., Reisfeld, R. A., and Cheresh, D. A.: Integrin alphavbeta3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 91, 8856-8860 (1994)

217. Schaller, M. D., Borgman, C. A., Cobb, B. C., Reynolds, A. B., and Parsons, J. T.: pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesion. Proc Natl Acad Sci USA 89, 5192-5196 (1992)

218. Hungerford, J. E., Compton, M. T., Matter, M. L., Hoffstrom, B. J., and Otey, C. A.: Inhibition of pp125FAK in cultured fibroblasts results in apoptosis. J Cell Biol 135, 1383-1390 (1996)

219. Frisch, S. M., Vuori, K., Ruoslahti, E., and Chan-Hui, P.-Y.: Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134, 793-799 (1996)

220. Nikiforov, M. A., Hagen, K., Ossovskaya, V. S., Connor, T. M., Lowe, S. W., Deichman, G. I., and Gudkov, A. V.: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 13, 1709-1719 (1996)

221. McGill, G., Shimamura, A., Bates, R., Savage, R. E., and Fisher, D. E.: Loss of matrix adhesion leads to rapid transformation-selective apoptosis in fibroblasts. J Cell Biol, 1997 (In Press)

222. Zhang, Z., Vuori, K., Reed, J. C., and Ruoslahti, E.: The alpha5beta1integrin supports survival of cells on fibronectin and up-regulates bcl-2 expression. Proc Natl Acad Sci USA 92, 6161-6165 (1995)

223. Frisch, S. M., Vuori, K., Kelaita, D., and Sicks, S.: A role for Jun-N-terminal kinase in anoikis; suppression by Bcl-2 and Crm-A. J Cell Biol 135, 1377-1382 (1996)

224. Rak, J., Mitsuhashi, Y., Erdos, V., Huang, S.-n., Filmus, J., and Kerbel, R. S.: Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol 131, 1587-1598 (1995)

225. Ojakian, G. K.: Tumor promoter-induced es in the permeability of epithelial cell tight junctions. Cell 23, 95-103 (1981)

226. Stoker, M., O'Neill, C., Berryman, S., and Waxman, V.: Anchorage and growth regulation in normal and virus-transformed cells. Intl J Cancer 3, 683-693 (1968)

227. Bates, R. C., Buret, A., van helden, D. F., Norton, M. A., and Burns, G. F.: Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125, 403-415 (1994)

228. Raff, M. C.: Social controls on cell survival and cell death. Nature 356, 397-400 (1992)

229. Varner, J. A., Emerson, D. A., and Juliano, R. L.: Integrin alpha5beta1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Mol Biol Cell 6, 725-740 (1995)

230. Sugahara, H., Kanakura, Y., Furitsu, T., Ishihara, K., Oritani, K., Ikeda, H., Kitayama, H., Ishikawa, J., Hashimoto, K., Kanayama, Y., and Matsuzawa, Y.: Induction of programmed cell death in human hematopoietic cell lines by fibronectin with very late antigen 5. J Exp Med 179, 1757-1766 (1995)

231. Guillemin, K. and Krasnow, M. A.: The hypoxic response: Huffing and HIFing. Cell 89, 9-12 (1997)

232. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., and Giaccia, A. J.: Transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 56, 3436-3440 (1996)

233. Graeber, T. G., Peterson, J. F., Tsai, M., Monica, K., Fornace, A. J., and Giaccia, A. J.: Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14, 6264-6277 (1994)

234. Spiro, I., Rice, G. C., Durand, R. E., Stickler, R., and Ling, C. C.: Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiol Oncol Biol Phys 10, 1275-1280 (1984)

235. Yao, K.-S., Clayton, M., and O'Dwyer, P. J.: Apoptosis in human adenocarcinoma HT29 cells induced by exposure to hypoxia. J Natl Cancer Inst 87, 117-122 (1995)

236. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J.: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996)

237. Hochachka, P. W., Buck, L. T., Doll, C. J., and Land, S. C.: Unifying theory of hypoxia tolerance: Molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93, 9493-9498 (1996)

238. Warburg, O.: On respiratory impairment in cancer cells. Science 124, 269-270 (1956)

239. Semenza, G. L., Roth, P. H., Fang, H., and Wang, G. L.: Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269, 23757-23763 (1994)

240. Hanahan, D. and Folkman, J.: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996)

241. Fandrey, J.: Hypoxia-inducible gene expression. Respiration Physiology 101, 1010 (1995)

242. Shweiki, D., Neeman, M., Itin, A., and Keshet, E.: Induction of vascular endothelial growth factor expression by hypoxia and glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 92, 768-772 (1995)

243. Shweiki, D., Itin, A., Soffer, D., and Keshet, E.: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992)

244. Hlatky, L., Tsionou, C., Hahnfeldt, P., and Coleman, C. N.: Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor upregulation and protein expression. Cancer Res 54, 6083-6086 (1994)

245. Dameron, K., Volpert, O., Tainsky, M., and Bouck, N.: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1585 (1994)

246. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143, 401-409 (1993)

247. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J.: Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324, 1-8 (1991)

248. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J.: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung Carcinoma. Cell 79, 315-328 (1994)

249. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Brikhead, J. R., Olsen, B. R., and Folkman, J.: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997)

250. Fidler, I. J. and Ellis, L. M.: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188 (1994)

251. Varner, J. A., Brooks, P. C., and Cheresh, D. A.: The integrin alphavbeta3: Angiogenesis and apoptosis. Cell Adhesion and Comm 3, 367-374 (1995)

252. Bischoff, J.: Cell adhesion and angiogenesis. J Clin Invest 99, 373-376 (1997)

253. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Varner, D. A.: Definition of two angiogenic pathways by distinct alphav integrins. Science 270, 1500-1502 (1995)

254. Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., and Cheresh, D. A.: Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994)

255. Hammes, H.-P., Brownlee, M., Jonczyk, A., Sutter, A., and Preissner, K. T.: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 2, 529-533 (1996)

256. Eastman, A.: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2, 275-280 (1990)

257. Hickman, J. A.: Apoptosis induced by anticancer drugs. Cancer Met Rev 11, 121-139 (1992)

258. Fung, C. Y. and Fisher, D. E.: p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 13, 808-811 (1995)

259. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C.: p53 mutations in human cancers. Science 253, 49-53 (1991)

260. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorenson, B., Montesano, R., and Harris, C. C.: Database of p53 gene somatic mutations in human tumors and cell lines. Nucl Acids Res 22, 3551-3555 (1994)

261. Vogelstein, B. and Kinzler, K. W.: p53 function and dysfunction. Cell 70, 523-526 (1992)

262. Donehower, L., Harvey, M., Slagle, B., McArthur, M., Montgomery, C., Butel, J., and Bradley, A.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221 (1992)

263. Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., and Donehower, L. A.: Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet 5, 225-229 (1993)

264. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H.: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990)

265. el Rouby, S., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R., and Newcomb, E. W.: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82, 3452-3459 (1993)

266. Sander, C. A., Yano, T., Clark, H. M., Harris, C., Longo, D. L., Jaffe, E. S., and Raffeld, M.: p53 mutation is associated with progression in follicular lymphomas. Blood 82, 1994-2004 (1993)

267. Fossa, S. D., Berner, A. A., Jacobsen, A. B., Waehre, H., Kvarstein, B., Urnes, T., Ogreid, P., Johansen, T. E., Silde, J., and Nesland, J. M.: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erB-2 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer 68, 572-578 (1993)

268. Allred, D. C., Clark, G. M., Elledge, r., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L.: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85, 200-206 (1993)

269. Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E., and Maiolo, A. T.: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81, 128-135 (1993)

270. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P.: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84, 1109-1114 (1992)

271. Florenes, V. A., Oyjord, T., Holm, R., Skrede, M., Borresen, A. L., Nesland, J. M., and Fodstad, O.: TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 69, 253-259 (1994)

272. Wada, M., Bartram, C. R., Nakamura, H., Hachiya, M., Chen, D., Borenstein, J., Miller, C. W., Ludwig, L., Hansen-Hagge, T. E., Ludwig, W., Reiter, A., Mizoguchii, H., and Koeffler, H. P.: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82, 3163-3169 (1993)

273. Silvestrini, R., Bennini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U.: p53 as independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85, 965-970 (1993)

274. Yeargin, J., Cheng, J., and Haas, M.: Role of the p53 tumor suppressor gene in the pathogenesis and in the suppression of acute lymphoblastic T-cell leukemia. Leukemia 6, 85S-91S (1992)

275. Yeargin, J., Cheng, J., Yu, A. L., Gjerset, R., Bogart, M., and Haas, M.: P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines. J Clin Invest 91, 2111-2117 (1993)

276. Sawan, A., Randall, B., Angus, B., Wright, C., Henry, J. A., Ostrowski, J., Hennessy, C., Lennard, T. W., Corbett, I., and Horne, C. H.: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 168, 23-28 (1992)

277. Starzynska, T., Bromley, M., Ghosh, A., and Stern, P. L.: Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66, 558-562 (1992)

278. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T.: p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994)

279. Komarova, E. A., Chernov, M. V., Franks, R., Wang, K., Armin, G., Zelnick, C. R., Chin, D. M., Bacus, S. S., Stark, G. R., and Gudkov, A. V.: Transgenic mice with a p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16, 1391-1400 (1997)

280. Gottlieb, E., Haffner, R., King, A., Asher, G., Gruss, P., Lonai, P., and Oren, M.: Transgenic mouse model for studying the transcriptional activity of the p53 protein: age-and tissue-dependent es in radiation-induced activation during embryogenesis. EMBO J 16, 1381-1390 (1997)

281. Dole, M., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P.: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54, 3253-3259 (1994)

282. Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nunez, G., and Castle, V. P.: Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55, 2576-2582 (1995)

283. Reed, J. C., Meister, L. M., Tanaka, S., Cuddy, M., Yum, S., Geyer, C., and Pleasure, D.: Differential expression of bcl-2 protooncogene in neuroblastoma and other tumors of neural origin. Cancer Res 51, 6529-6538 (1991)

284. Castle, V. P., Heidelberger, K. P., Bromberg, J., Ou, X., Dole, M., and Nunez, G.: Expression of the apoptosis-suppressing protein Bcl-2 in neuroblastoma is associated with poor stage disease, unfavorable histology and N-myc amplification. Am J Pathol 143, 1542-1550 (1993)

285. Miyashita, T. and Reed, J. C.: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81, 151-157 (1993)

286. Kamesaki, S., Kamesaki, H., Jorgensen, T. J., Tanizawa, A., Pommier, Y., and Cossman, J.: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase-II induced DNA strand breaks and their repair. Cancer Res 53, 4251-4256 (1993)

287. Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., and Van Marck, E.: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72, 354-360 (1995)

288. Lipponen, P., Pietilainen, T., Kosma, V. M., Aaltomaa, S., Eskelinen, M., and Syrjanen, K.: Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177, 49-55 (1995)

289. Hurlimann, J., Larrinaga, B., and Vala, D. L.: Bcl-2 protein in invasive ductal breast carcinomas. Virchows Archiv 426, 163-168 (1995)

290. Joensuu, H., Pylkkanen, L., and Toikkanen, S.: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145, 1191-1198 (1994)

291. Gee, J. M., Robertson, J. F., Ellis, I. O., Willsher, P., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blamey, R. W., and Nicholson, R. I.: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59, 619-628 (1994)

292. Strobel, T., Swanson, L., Korsmeyer, S., and Cannistra, S. A.: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93, 14094-14099 (1996)

293. Danen-Van Oorschot, A. A. M., Fischer, D. F., Grimbergen, J. M., Klein, B., Zhuang, S.-M., Falkenburg, J. H. F., Blackendorf, C., Quax, P. H. A., Van der Eb, A. J., and Noteborn, M. H. M.: Apoptin induces apoptosis in human transformed and malignant cells but not in transformed cells. Proc Natl Acad Sci USA 94, 5843-5847 (1997)

294. Durand, R. E. and Sutherland, R. M.: Effects of intercellular contact on repair of radiation damage. Exp Cell Res 71, 75-80 (1972)

295. Fridman, R., Giaccone, G., Kanemoto, T., Martin, G. R., Gazdar, A. F., and Mulshine, J. L.: Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer lines. Proc Natl Acad Sci USA 87, 6698-6702 (1990)

296. Fuks, Z., Vlodavsky, I., Andreeff, M., McLoughlin, M., and Haimovitz-Friedman, A.: Effects of extracellular matrix on the response of endothelial cells to radiaiton in vitro. Eur J Cancer 28A, 725-731 (1992)

297. Kobayashi, H., Man, S., Kapitain, S. J., Teicher, B. A., and Kerbel, R. S.: Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90, 3294-3298 (1993)

298. Kerbel, R. S., Brauer, M. J., Powers, V. C., Wu, J. J., Umansky, S. R., Tomei, L. D., and Bar, P. J.: Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harbor Symp. Quant. Biol Mol Gen Cancer 59, 661-672 (1995)

299. Whitacre, C. M. and Berger, N. A.: Factors affecting topotecan-induced programmed cell death: adhesion protects cell from apoptosis and impairs cleavage of poly(ADP-Ribose) polymerase. Cancer Res 57, 2157-2163 (1997)

300. Hall, E.: Radiobiology for the radiobiologist, Fourth Ed., Lippincott Company, Philadelphia, PA (1994)

301. Moulder, J. E. and Rockwell, S.: Tumour hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5, 313-341 (1987)

302. Fowler, J. F., Adams, G. E., and Denekamp, J.: Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev 3, 227-256 (1976)

303. Dische, S.: Chemical sensitizers for hypoxic cells - a decade of experience in clinical radiotherapy. Radiother Oncol 3, 97-115 (1985)

304. Gibbs, J., Oliff, A., and Kohl, N. E.: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77, 175-178 (1994)

305. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C.: Evidence that farnesyltransferase inhibitors suppress transformation by interfering with Rho activity. Mol Cell Biol 15, 6613-6622 (1995)

306. Qiu, R.-G., Chen, J., McCormick, F., and Symons, M.: A role for Rho in Ras transformation. Proc Natl Acad Sci USA 92, 11781-11785 (1995)

307. Esteve, P., del Peso, L., and Lacal, J. C.: Induction of apoptosis by rho in NIH3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis. Oncogene 11, 2657-2665 (1995)

308. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C.: Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 57, 708-713 (1997)